SMMT

Summit Therapeutics
$17.00
−$0.54 (−3.08%)Sep 10, 2026
0.9PoorMoatMint rating

MoatMint rates Summit Therapeutics (SMMT) 0.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.4 out of 10.

Key metrics

The numbers that frame SMMT today
Market cap
$13.56B
P/E (TTM)
-15.8
EV / FCF
-28.6
ROIC
-296.2%
Div yield
0%
Debt / equity
0.0
52wk Low
$12.07
52wk High
$29.23

SMMT stock rating

How SMMT scores on quality, value, growth, momentum and financial health
0.9out of 10
Low overallNeutral business, expensive price
Quality0.4
Growth2.1
Momentum3.1
Value2.9
Financial Health3.1

Growth

Revenue and earnings trend for SMMT
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about SMMT
Is Summit Therapeutics a good buy?
No. Summit Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Summit Therapeutics is selling at a high price.
What is the market capitalization of SMMT?
Summit Therapeutics's market capitalization is $13.56B.
What is the P/E ratio for SMMT stock?
Summit Therapeutics's current P/E ratio is -15.8.
What is the 52-week high for SMMT stock?
The 52-week high for Summit Therapeutics is $29.23. The current close of $17.00 is 41.8% below that high.
What is the 52-week low for SMMT stock?
The 52-week low for Summit Therapeutics is $12.07. The current close of $17.00 is 40.8% above that low.
Does SMMT stock pay dividends?
Summit Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SMMT?
Summit Therapeutics's Debt / Equity ratio is 0.03.